Genetic Screening and Tissue Banking: The New Standard for Parents

Modern medicine is reshaping how parents approach prenatal and newborn care. Two key advancements - genetic screening and tissue banking - are giving families tools to prepare for potential health challenges and secure future treatment options.

Key Takeaways:

• Genetic Screening: Tests like Non-Invasive Prenatal Testing (NIPT) and Whole Genome Sequencing (WGS) help identify genetic risks during pregnancy. Early detection enables parents to plan for specialized care if needed.
• Tissue Banking: Stem cells from umbilical cords and placentas can treat over 80 diseases, including leukemia and sickle cell disease. Stored cells may also benefit family members and support emerging therapies.
• Costs: Tissue banking plans range from $1,078 annually to $5,979 for lifetime storage. Discounts are often available for bundled services or prepayment.

These advancements are not just theoretical - they are already changing lives, with real-world success stories and growing medical applications. Parents should explore these options early in pregnancy to make informed decisions about their child's future health.

What Is Genetic Screening and How Does It Work?

Genetic screening is a non-invasive test designed to assess the likelihood of a fetus developing genetic disorders. Unlike diagnostic tests, which confirm specific conditions, genetic screening provides a risk estimate, labeling results as either "high-risk" or "low-risk." This distinction helps parents make informed decisions about further steps.

The process often begins with carrier screening, which can be done before or early in pregnancy. Using a simple blood draw or cheek swab, this test identifies whether parents carry genes for inherited conditions like cystic fibrosis, spinal muscular atrophy, or sickle cell disease. During the first trimester (weeks 10–14), blood tests measure markers such as PAPP-A and hCG levels, which are paired with a nuchal translucency ultrasound to check for chromosomal abnormalities like Down syndrome. Another option, cell-free DNA (cfDNA) screening - also called NIPT - can be done starting at week 10 and is known for its high detection rates.

In the second trimester (weeks 15–22), maternal serum screening (commonly the Quad screen) measures substances like Alpha-fetoprotein (AFP) to assess risks for neural tube defects and other chromosomal issues. Around weeks 18 to 22, a detailed anatomy ultrasound examines the baby’s physical development. After birth, newborn screening involves a heel prick blood sample, which most U.S. states use to test for 30 to 50 serious but treatable conditions.

The Genetic Screening Process

The screening process unfolds in stages, providing more detailed insights as pregnancy progresses. Carrier screening, done before or early in pregnancy, uses a blood draw or swab to detect if parents carry genes for common inherited disorders. If both parents are carriers of the same condition, their child has a 25% chance of inheriting it.

First-trimester screening combines blood tests with ultrasound imaging. For cfDNA tests, a fetal fraction of 2–4% is necessary for accuracy. However, about 10% of women over 250 pounds may need a retest due to lower fetal DNA levels.

Second-trimester screening adds more detail. The Quad screen measures four substances in maternal blood, while the anatomy ultrasound evaluates the baby’s organs, limbs, and overall development. Standard serum screenings carry about a 5% chance of false positives, meaning follow-up testing might be needed.

If screening results indicate a high risk, diagnostic testing becomes an option. Chorionic Villus Sampling (CVS) can be performed between weeks 10 and 13, while amniocentesis is available between weeks 15 and 20. These procedures are highly accurate, with a 98% to 99% success rate in confirming genetic or chromosomal conditions.

"Prenatal testing should be offered to every woman, regardless of age or family history." - John Williams, MD, Maternal-Fetal Medicine Specialist, Cedars-Sinai

Why Parents Choose Genetic Screening

Genetic screening offers parents a chance to prepare. Identifying genetic conditions before birth allows families to plan deliveries at hospitals equipped with Neonatal Intensive Care Units (NICU) and specialists who can provide immediate care. This preparation can be life-saving in cases requiring urgent medical attention.

Screening also enables tailored care approaches. For instance, Rapid Whole Genome Sequencing (rWGS) can diagnose illnesses in critically ill infants faster than traditional methods, helping doctors customize treatments based on the child’s genetic makeup. Similarly, early detection of developmental conditions like autism spectrum disorder through tests like chromosomal microarrays can allow families to start intervention programs earlier.

Beyond medical planning, screening data connects families to support networks and resources, making it easier to navigate challenges and access care.

"Every patient should receive prenatal counseling before they get any type of prenatal screening and diagnostic tests, so they better understand the risks and benefits of these tests." - Tania Esakoff, MD, Maternal-Fetal Medicine Specialist, Cedars-Sinai

Privacy and Ethics in Genetic Testing

Genetic data is deeply personal, and concerns about its use are common. The Genetic Information Nondiscrimination Act (GINA) offers federal protection against misuse of genetic data by employers and health insurers. However, it doesn’t cover life insurance, disability insurance, or long-term care insurance.

Parents are encouraged to ask testing providers about their data storage and sharing practices. Trusted providers uphold strict confidentiality standards and require explicit consent before sharing data with third parties, including researchers. This transparency helps families make informed choices about genetic screening and diagnostic tests.

"A positive screening test result for aneuploidy means that your fetus is at higher risk of having the disorder compared with the general population. It does not mean that your fetus definitely has the disorder." - American College of Obstetricians and Gynecologists (ACOG)

Tissue Banking: Preserving Stem Cells for Future Medical Use

Tissue banking involves collecting stem cells from a newborn's umbilical cord and placenta right after birth, then storing them cryogenically for potential medical use in the future. Unlike genetic screening, which identifies potential health risks, tissue banking focuses on preserving biological materials that could help treat illnesses your child - or even other family members - might face years down the road.

The process begins immediately after the umbilical cord is clamped and cut. Medical staff collect cord blood, cord tissue, and placental tissue within minutes. A courier then transports the collection kit to a specialized lab. There, technicians separate the stem cells and add a cryoprotectant before cooling them to -196°F in liquid nitrogen tanks. Research confirms that stem cells stored this way for up to 23.5 years remain viable. This long-term preservation supports a variety of banking options tailored to different medical applications.

Types of Tissue Banking Available

Parents today can choose from four main types of tissue banking, each designed to preserve specific stem cells for potential therapeutic use.

• Cord blood banking: This stores hematopoietic stem cells (HSCs), which the FDA has approved for treating over 80 conditions, including leukemia, lymphoma, sickle cell disease, thalassemia, and inherited immune deficiencies. These cells help rebuild blood and immune systems. Typically, 40 to 50 mL of cord blood is required for effective storage. Even with delayed cord clamping (30–60 seconds), enough blood - around 100 to 120 mL - usually remains for collection.
• Cord tissue banking: This preserves mesenchymal stem cells (MSCs) found in Wharton’s Jelly, the soft tissue surrounding the umbilical cord’s blood vessels. These cells can develop into bone, cartilage, nerve, and muscle tissues. While not yet FDA-approved for treatments, MSCs are being studied in over 300 clinical trials for conditions like autism, cerebral palsy, multiple sclerosis, and spinal cord injuries.
• Placental tissue banking: This stores additional MSCs along with amniotic epithelial and chorion trophoblast stem cells from the placenta. These cells show promise in wound healing and reducing inflammation, with ongoing research into their use for cardiovascular and autoimmune conditions.
• Exosome banking: Exosomes are tiny vesicles that act as cellular messengers, playing a role in immune regulation and healing. Though not yet FDA-approved for treatment, exosomes are being studied in clinical trials. At present, they are stored for possible future research or trial participation. This service is unavailable in California.

Medical Benefits of Newborn Tissue Banking

Tissue banking offers both immediate and long-term medical benefits. Cord blood HSCs have already been used in over 40,000 stem cell transplants worldwide, successfully treating blood cancers, bone marrow disorders, and immune deficiencies.

Cord and placental tissue MSCs are expanding the possibilities for treatment. Studies indicate that combining HSCs with MSCs in transplants can improve engraftment rates and lower the risk of Graft vs. Host Disease without compromising safety. This makes storing multiple tissue types even more appealing.

Another advantage is family compatibility. Banked stem cells are a perfect genetic match for the child they were collected from. For siblings, there’s a 25% chance of being a perfect match and a 50% chance of a partial match. This means the stored cells could potentially benefit siblings, parents, or even grandparents. With estimates suggesting that 1 in 3 Americans may benefit from regenerative medicine in their lifetime, the likelihood of using these banked cells continues to grow as new treatments emerge.

Americord's Tissue Banking Services

Americord offers families a range of comprehensive tissue banking services to safeguard these critical resources. Their plans include options ranging from cord blood-only storage to more extensive packages covering cord blood, cord tissue, placental tissue, and both newborn and maternal exosome banking. All plans feature CryoMaxx™ Processing, a proprietary method designed to maximize stem cell recovery while preserving essential growth factors and cytokines.

Americord’s facilities are AABB-accredited, ensuring adherence to strict quality and safety standards. Their unique 5-compartment storage vials allow cord blood to be divided into multiple portions, which could support up to five separate treatments from a single collection - an important advantage for families needing multiple therapies over time.

As of 2023, Americord has stored over 22,000 cryogenically preserved units, showcasing their experience and scale. They also offer a $110,000 quality guarantee - the highest in the industry - covering the cost of finding alternative stem cell sources if a stored unit fails during treatment. Pricing depends on the selected plan and storage duration, with clear cost breakdowns provided to help families make informed decisions.

Costs and Practical Factors to Consider

Understanding the financial and logistical aspects of tissue banking is a key step in making an informed decision.

What Genetic Screening and Tissue Banking Cost

Tissue banking involves three main expenses: the kit, processing, and long-term storage. As of March 2026, Americord offers an Annual Storage Plan priced at $1,078, which includes a $199 kit and $81 for shipping. For those seeking longer-term options, the 20-Year Essential Plan costs $3,779, with the option to pay $145 per month over 24 months. Alternatively, the Lifetime Essential Plan is available for $5,979, or $237 per month over 24 months. This month, Americord is offering discounts: 15% off multi-service 20-year plans and 30% off multi-service lifetime plans.

Genetic screening for stored stem cells is an optional service and not included in the standard packages. Prepaying for 20-year or lifetime storage can result in substantial savings compared to paying annual fees, which typically range from $150 to $300 per year.

Understanding the Long-Term Value

The value of tissue banking goes far beyond the initial costs. Lifetime storage ensures that stem cells remain accessible throughout your child’s life, offering the potential to benefit from future advancements in medical treatments. Weighing both the cost and the potential long-term benefits is crucial when deciding on a provider.

How to Choose the Right Provider

Choosing the right tissue banking provider requires careful evaluation. Look for AABB accreditation or American Association of Tissue Banks (AATB) certification to confirm compliance with strict safety and quality standards. Ensure the laboratory also has CLIA certification, which guarantees accuracy and quality in testing.

Ask about the processing methods used - automated systems are often more reliable and technologically advanced than manual ones. Review the provider's transportation protocols to confirm that they use validated, temperature-controlled methods and high-quality collection kits to protect the viability of stem cells during transit.

Additionally, consider the provider's track record and experience in long-term storage. Before signing, confirm ownership rights and informed consent policies. To maximize future therapeutic options, explore bundled services, such as banking cord blood, cord tissue, and placental tissue. These combined services can expand the scope of potential medical applications for your child.

Conclusion: Taking Action for Your Child's Future Health

Building on the earlier discussion of early diagnosis, tissue banking plays a key role in preparing for future healthcare needs. Together with genetic screening, these steps offer a forward-thinking approach to safeguarding your child's health. Prenatal and preconception genetic screening can detect inherited or chromosomal conditions early, giving families the opportunity to plan for specialized care and delivery. Meanwhile, banking newborn stem cells at birth preserves a resource that is approved by the FDA to treat over 80 conditions and is being studied in clinical trials for autism, cerebral palsy, diabetes, and other neurological disorders.

Timing is critical - stem cell collection can only happen immediately after delivery. This means decisions need to be made during pregnancy. Start by discussing carrier and prenatal screening options with your OB/GYN or midwife early on. Then, during your second or third trimester, explore tissue banking options. Compare providers based on key factors like AABB accreditation, FDA registration, processing techniques, and long-term storage assurances.

Americord is one provider offering a range of services tailored to family needs. They provide banking for cord blood, cord tissue, placental tissue, and exosome preservation, with flexible plans to suit different requirements. Prepaying for long-term storage may also reduce costs. For detailed pricing, plan options, and current offers, reach out to Americord directly.

Once you've chosen a provider, completing the process is straightforward: enroll, receive your collection kit, bring it to the hospital, and ensure the sample is shipped within 72 hours. Your birth team should be prepared to collect the sample immediately after clamping. Expect initial viability results within 48 hours, with final testing completed in about 14 days.

Ultimately, your decision should reflect your family's goals, budget, and comfort level with potential risks. Tissue banking offers access to both current medical treatments and the promise of future therapies. Taking action now helps secure opportunities for advanced care down the road.

FAQs

Which genetic screening tests should I consider, and when?

Prenatal genetic screening usually happens during the first and second trimesters. Early on, cell-free DNA (cfDNA) screening can identify conditions like Down syndrome starting at 10 weeks. Later in the second trimester, tests like the quad screen and ultrasounds help evaluate genetic risks and check for structural issues. If screenings suggest an elevated risk, diagnostic tests such as CVS or amniocentesis might be advised. Talk to your healthcare provider to decide what’s right for you.

If my screening is high-risk, what happens next?

If your screening results indicate a high risk, your healthcare provider will reach out to you within 24–48 hours. They might suggest further testing or connect you with a specialist to gain a clearer understanding of your condition and decide on the best course of action. This approach helps ensure you get the care and support you need.

Is tissue banking worth it if my family has no known risks?

Tissue banking holds promise even when there are no apparent health concerns. By preserving mesenchymal stem cells (MSCs), you’re essentially storing a resource that could play a role in addressing a range of medical conditions down the line. Families with existing health risks might feel the urgency more acutely, but this proactive measure offers everyone a chance to prepare for advancements in stem cell therapies. It’s a forward-thinking way to potentially secure more medical options for your child’s future.